SmarterAnalyst
Johnson & Johnson’s single dose COVID-19 vaccine granted for WHO emergency
Johnson & Johnson’s single-dose COVID-19 vaccine, developed by Johnson & Johnson (Janssen)’s Janssen Pharmaceutical Companies, has been issued by the World Health Organization (WHO) with an emergency use list (EUL). The world’s largest healthcare company has designed the vaccine to prevent COVID-19 in individuals 18 years and older. The data released from the Phase 3 ENSEMBLE study showed that Johnson & Johnson (JNJ)’s COVID-19 single shot vaccine has a favorable tolerance profile. In addition, the study confirmed that the reduction in symptomatic COVID-19 disease in individuals who received the vaccine compared to individuals who received the placebo was 67%. Furthermore, the data confirm the efficacy of the vaccine for 85% in preventing serious diseases in all studied regions, and it showed that the vaccine is protected against hospitalization and death due to COVID-19 in countries with different variants, which is 28 days after vaccination begins. Last December, Johnson & Johnson and Gavi, the Vaccine Alliance, agreed in principle to support the COVAX facility. Both are likely to enter into a pre-purchase agreement (APA) that will deliver 500 million doses of the company’s vaccine to COVAX by 2022. (See Johnson & Johnson stock analysis on TipRanks) Paul & Stoffels, Johnson & Johnson’s executive committee member, Paul Stoffels, said: ‘The WHO lists our single-shot COVID-19 vaccine furthering our commitment to this pandemic and to help stem our unwavering commitment to equitable access. “” Achieving this important prerequisite for the distribution of our vaccine through the COVAX facility led by Gavi is an important step forward in making our vaccine accessible to all, “Stoffels added. Over the past few months, the company has also received an emergency authorization (EUA) for the vaccine in the US from the Food and Drug Administration (FDA) and an interim authorization in Canada, along with a conditional marketing (CMA) in the European Union. On January 27, JP Morgan analyst Chris Schott raised the stock’s price target to $ 175 (9.7% upside potential) from $ 157 and repeated a Hold rating “following the company’s Q4 results” . ” The consensus rating among analysts is a strong buy based on 10 buys versus 1 hold. The average price target for analysts stands at $ 189.90 and implies an upward potential of 19% to current levels. Shares have risen 25.5% over the past year. In addition, Johnson & Johnson achieved a ‘Perfect 10′ from the TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations. Related News: Altimmune Expands Lonza Partnership to Support AdCOVID Cardinal Health Ink Production $ 1 Billion to Sell Cordis Business Sanofi, Translate Bio Kick Off Human COVID-19 Vaccine Trial; Shares Rise 5% More Recent Articles by Smarter Analyst: Century Casinos Profits 4% On 4Q Profits Win Four Corners Buy Caliber Collision Property for $ 1.9 Million Charles Schwab’s February. Brokerage accounts and client assets climb the Lifestyle Bumps Up Quarterly Dividend by 5.8%; Street sees 10% upside down